Regulatory Landscape for Pharmaceutical Products: The company's reliance on FDA approvals and sNDAs for its dermatological products means that changes in regulatory policies or delays in review processes (e.g., for sBCC and expanded AK treatment areas) can significantly impact market access and revenue growth. [cite: 1, 3, 6 in previous turn]

Competition and Market Adoption in Dermatology: The competitive nature of the dermatological treatment market, particularly for conditions like actinic keratosis and acne, means that the adoption rate of Biofrontera's photodynamic therapy (PDT) platform, Ameluz, against existing and emerging treatments is crucial for commercial success and market share. [cite: 10, 14, 26 in previous turn]

Intellectual Property Protection and Litigation: Biofrontera's ability to protect its patents and manage intellectual property disputes, as shown by the recent favorable U.S. Patent Office decision against Sun Pharma's patent, is a significant factor. Positive outcomes strengthen its market position, while adverse rulings could lead to increased competition or legal costs. [cite: 6 in previous turn]